Loading
A phase 2 trial of ABSK061, CAPOX in non-small-cell lung cancer and small-cell lung cancer, run by Abbisko Therapeutics Co, Ltd, now recruiting.
A Phase 2 Clinical Study of ABSK061 and ABSK043 is a phase 2 interventional study registered as NCT06632262 by Abbisko Therapeutics Co, Ltd, with 202 participants planned, started 2024-11-13 and due to reach its primary completion in 2029-11-30. Interventions recorded: ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX. Conditions listed: HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Abbisko Therapeutics, Small-cell lung cancer, Non-small-cell lung cancer.
Shares CAPOX (capecitabine, oxaliplatin), Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/